Cardiac warning over osteoporosis drug

Europe's drug watchdog has moved to restrict the use of osteoporosis drug strontium ranelate (Protos), citing an increased risk of myocardial infarction compared with placebo.

A European Medicines Agency committee said data on the drug "were of concern", and would be evaluated further in an expedited, in-depth review.

In the meantime, the committee recommended avoiding strontium ranelate in people with current or previous